Compare General Mills, Inc. (GIS) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Mills, Inc. vs Inovio Pharmaceuticals Inc — how do they compare? General Mills, Inc. trades at $38.78 (market cap $19.46B), while Inovio Pharmaceuticals Inc trades at $1.16 (market cap $96.26M). The key difference: General Mills, Inc. is far larger — about 202.2× Inovio Pharmaceuticals Inc's market cap, and General Mills, Inc. pays a 6.69% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| GIS | INO | |
|---|---|---|
Market Cap | $19.46B | $96.26M |
Sector | Consumer Staples | Health |
52-Week High | $51.27 | $2.87 |
52-Week Low | $32.17 | $1.05 |
Enterprise Value | $32.95B | $67.27M |
Dividend Yield | 6.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Mills (GIS) trades at $36.46, down 0.38% on the day, with a neutral technical signal and mixed earnings history. The stock shows a low P/E of 9.23 and pays a dividend, but faces net income margin pressure at -0.48% for 2026. Recent news highlights partnerships in regenerative agriculture and cost-saving initiatives targeting $3 billion by 2030 to combat soft consumer demand.
Outlook remains cautious with sales pressure expected in 2027, though valuation appears attractive. Key risks include competitive pressures and margin recovery challenges. Analyst consensus is mixed with a hold-heavy rating, suggesting patience for turnaround execution amid economic headwinds.
INO trades at $1.16 with no recent price movement, reflecting its speculative biotech profile. The company shows consistent quarterly earnings beats but operates with minimal revenue ($65K in 2025) and significant losses (-$85M net income). Technical indicators are bearish overall, though some oscillators suggest potential oversold conditions. Recent news highlights the critical FDA decision for INO-3107 in October 2026 as the primary near-term catalyst.
The investment case hinges entirely on regulatory approval of INO-3107, with analysts maintaining a cautiously optimistic stance (53% buy ratings). However, substantial financial risks persist including negative cash flow, high burn rate, and shareholder litigation. Successful FDA approval could drive significant upside, while rejection would likely exacerbate financial pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
